Pembrolizumab is a highly selective IgG4-kappa humanized monoclonal antibody against PD-1 receptors. It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype containing a stabilizing S228P Fc mutation. It contains 32 cysteine residues and the complete folded molecule includes 4 disulfide linkages as interchain bonds and 23 interchain bonds. It was developed by Merck & Co and first approved for the treatment of metastatic malignant melanoma by the FDA on September 4, 2014, becoming the first approved therapy against PD-1. In the time since its initial approval, pembrolizumab has been granted approval in the treatment of a wide variety of cancers.
Pembrolizumab is indicated for the following conditions:
For all approved adult indications, pembrolizumab may be used for an additional 6 weeks at 400mg weekly.
Cedars Sinai Medical Center, Duarte, California, United States
University of Chicago, Chicago, Illinois, United States
Providence Portland Medical Center, Portland, Oregon, United States
Moffitt Cancer Center, Tampa, Florida, United States
Georgia Cancer Center at Augusta University, Augusta, Georgia, United States
John Theurer Cancer Center at Hackensack UMC, Hackensack, New Jersey, United States
Medstar Washington Hospital Center, Washington, District of Columbia, United States
Fudan University Shanghai Cancer Center ( Site 2500), Shanghai, Shanghai, China
Women s Hospital School of Medicine Zhejiang University ( Site 2511), Hangzhou, Zhejiang, China
Anhui Cancer Hospital-Gynecological Oncology ( Site 2509), Hefei, Anhui, China
Universitair Ziekenhuis Antwerpen, Edegem, Belgium
Wake Forest Baptist Health Sciences, Winston-Salem, North Carolina, United States
Tufts Medical Center, Boston, Massachusetts, United States
Christiana Care Health Services, Christiana Hospital, Newark, Delaware, United States
BRCR Global, Plantation, Florida, United States
Valkyrie Clinical Trials, Los Angeles, California, United States
UCLA Hematology/Oncology, Los Angeles, California, United States
Memorial Healthcare System, Hollywood, Florida, United States
Algemeen Ziekenhuis Klina, Brasschaat, Belgium
City of Hope, Duarte, California, United States
Winship Cancer Instituted of Emory University, Atlanta, Georgia, United States
Oregon health, Portland, Oregon, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.